Mannan-binding lectin (MBL) is a plasma protein involved in the innate immune response. It binds to a number of micro-organisms and promotes killing of these through complement activation either directly or through opsonization. Clinical evidence indicates that in a variety of situations genetically determined low MBL levels are associated with increased susceptibility to infections. Infusions of plasma-derived MBL into MBL-deficient individuals was found to be safe in preliminary trials, but we considered that sufficient production and product safety could only be achieved through synthesis of recombinant MBL. A transfected human cell line produces MBL showing the same biological activity as plasma-derived MBL, and an essentially identical profile on MS. The production has been scaled up and clinical trials will start this year.
Skip Nav Destination
Article navigation
August 2003
- PDF Icon PDF LinkFront Matter
Conference Article|
August 01 2003
Recombinant mannan-binding lectin (MBL) for therapy
J.C. Jensenius;
J.C. Jensenius
1
*Department of Medical Microbiology and Immunology, University of Aarhus, Denmark
1To whom correspondence should be addressed (e-mail j.c.jensenius@immunology.au.dk).
Search for other works by this author on:
P.H. Jensen;
P.H. Jensen
†NatImmune A/S, Copenhagen, Denmark
‡Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
Search for other works by this author on:
K. McGuire;
K. McGuire
†NatImmune A/S, Copenhagen, Denmark
Search for other works by this author on:
J.L. Larsen;
J.L. Larsen
†NatImmune A/S, Copenhagen, Denmark
Search for other works by this author on:
S. Thiel
S. Thiel
*Department of Medical Microbiology and Immunology, University of Aarhus, Denmark
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2003 Biochemical Society
2003
Biochem Soc Trans (2003) 31 (4): 763–767.
Citation
J.C. Jensenius, P.H. Jensen, K. McGuire, J.L. Larsen, S. Thiel; Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans 1 August 2003; 31 (4): 763–767. doi: https://doi.org/10.1042/bst0310763
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.